Evidence map›Paper›PMID 36305131›Full record

ArticleCurrent cancer drug targets2023

Impact of GSTT1 and GSTM1 Polymorphisms in the Susceptibility to Philadelphia Negative Chronic Myeloid Leukaemia.

Abozer Y Elderdery, Hadeil M E Idris, Entesar M Tebien, Nada Abdalfatah Diab, Siddiqa M A Hamza, Bandar A Suliman, Abdulaziz H Alhamidi, Nawal Eltayeb Omer, Jeremy Mills

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Glutathione-Dependent Pathways in Cancer Cells.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Abozer Y ElderderyDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia.
Hadeil M E IdrisCollege of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
Entesar M TebienCollege of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
Nada Abdalfatah DiabUniversity of Khartoum/ Medical Laboratory Science Programme, Alhyatt University College, Khortoum, Sudan.
Siddiqa M A HamzaDepartment of Pathology, College of Medicine, Umm Alqura University, Algunfuda, Saudi Arabia.
Bandar A SulimanCollege of Applied Medical Sciences, Taibah University, Medina, Saudi Arabia.
Abdulaziz H AlhamidiClinical Laboratory Sciences Department, College of Applied Medical Science, King Saud University, Riyadh, Saudi Arabia.
Nawal Eltayeb OmerFaculty of Medicine, Department of Pathology, Assafa College, Khartoum, Sudan.
Jeremy MillsSchool of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
Shaqra University · SAAl Jouf University · SAKing Saud University · SATaibah University · SAUmm al-Qura University · SAUniversity of Khartoum · SDUniversity of Portsmouth · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOur research aimed to clarify the role of genetic polymorphisms in GST (T1 and M1) in the development of Ph-ve CML. MATERIALS AND

methodsWe report on a case-control study with 126 participants, divided into 26 patients with Ph-ve CML (57.7% male, 42.3% female) and 100 healthy volunteers (51% male, 49% female) with no medical history of cancer as a control population. All Ph-ve CML patients were diagnosed according to standard hematologic and cytogenetic criteria based on CBC, confirmed by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) to determine the presence or absence of the BCRABL gene, followed by bone marrow (BM) examination.

resultsOf the 26 studied cases, 50% had the GSTT1 null genotype against 21% of the control group, a statistically significant difference (CI= 1.519 - 9.317; p-value= 0.004). The GSTM1 null genotype was detected in 23.1% of cases and 35% of controls, a difference not statistically significant (OR= 0.557; CI= 0.205-1.515; p-value= 0.252). The distribution of GSTT1 and GSTM1 polymorphisms was also examined according to gender, age and ethnic grouping; these findings revealed no statistically significant differences.

conclusionOur study reveals a strong correlation between GSTT1 polymorphism and Ph-ve CML, whereas the data for GSTM1 polymorphisms indicates no role in the initial development of the disease. More studies are required to further clarify these and other genes' roles in disease development.

Indexed as

Genetic Predisposition to DiseaseLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCase-Control StudiesFemaleGenotypeGlutathione TransferaseHumansMalePolymorphism, Geneticglutathione S-transferase T1Glutathione TransferaseBCR-ABL1CMLGSTM1GSTT1null genotypePhiladelphia negative and Sudan

Identifiers

PMID36305131
OpenAlexW4307454614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.